Cytopenia clinical trials at University of California Health

2 in progress, 1 open to eligible people

Showing trials for

  • Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients

    open to eligible people ages 18 years and up

    This observational, multi-center study aims to collect data in order to develop a novel, minimally invasive diagnostic tool for MDS based on peripheral blood profiling of circulating hematopoietic stem and progenitor cells (cHSPCs) using single-cell RNA sequencing and DNA sequencing.

    at UCSD

  • Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

    Sorry, not currently recruiting here

    Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously [SC]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it. The participants will be treated with mezagitamab for up to 6 months. During the study, participants will visit their study clinic several times. Participants who complete the TAK-079-3002 study or do not have any response to study treatment by week 16 (according to study criteria) will be given the opportunity to participate in a continuation study to receive open label mezagitamab (if they are eligible and the site is able to open the continuation study).

    at UCSD

Our lead scientists for Cytopenia research studies include .

Last updated: